ABBOTT PARK, Ill., Feb. 8, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) introduces Similac SimplySmart, an innovative BPA-free baby bottle designed to improve the bottle feeding experience for parents and babies through advanced features that provide comfort and convenience. This unique bottle, designed by experts in infant nutrition, incorporates insights from moms ... read more

ABBOTT PARK, Ill., Feb. 1, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, Feb. 15, 2012. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a presentation on the company at 8 a.m. ... read more

ABBOTT PARK, Ill., Jan. 25, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2011. -- Diluted earnings per share, excluding specified items, were $1.45, at the high end of Abbott's ... read more

ABBOTT PARK, Ill., Jan. 18, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) will begin implementing Abbott's STARLIMS® software-based laboratory information management system (LIMS) as part of the agency's initiative to enhance FDA testing laboratories. STARLIMS LIMS software ... read more

ABBOTT PARK, Ill., Jan. 4, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2011 financial results on Wednesday, Jan. 25, 2012, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. ... read more

ABBOTT PARK, Ill., Dec. 22, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit((TM)) drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in ... read more

ABBOTT PARK, Ill. and URBANA, Ill., Dec. 19, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) and the University of Illinois at Urbana-Champaign announced today they have established the first-ever multi-disciplinary nutrition and cognition research center, which will be located on the Urbana campus. The Center for Nutrition, ... read more

ABBOTT PARK, Ill., Dec. 15, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 30th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2012. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on the company at ... read more

ABBOTT PARK, Ill. and IRVING, Texas, Dec. 12, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs). The agreement is in ... read more

ABBOTT PARK, Ill., Dec. 9, 2011 /PRNewswire/ -- The board of directors of Abbott <font size="2" face="Arial">(NYSE: ABT)</font> today declared a quarterly common dividend of 48 cents per share. This marks the 352nd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is ... read more

ABBOTT PARK, Ill., Dec. 8, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb(TM) bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME(TM) Everolimus Eluting ... read more

ABBOTT PARK, Ill., Nov. 30, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received clearance from the U.S. Food and Drug Administration for a fully-automated 25-OH Vitamin D assay performed on its widely used ARCHITECT(®) laboratory testing platform. Published data from the Third National Health ... read more

DES PLAINES, Ill., Nov. 28, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. (GSK) to include the development of an additional companion diagnostic test in support of GSK's cancer immunotherapy research program. Companion diagnostic tests are ... read more

ABBOTT PARK, Ill., Nov. 21, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) received approval from the U.S. Food and Drug Administration (FDA) for a new Chagas in vitro diagnostic test. The ABBOTT ESA Chagas is the first FDA-approved supplemental test that detects antibodies to Trypanosoma cruzi (T. cruzi), a parasite found ... read more

ORLANDO, Fla., Nov. 15, 2011 /PRNewswire/ -- Final results were presented today from the AIM-HIGH study, a National Heart, Lung and Blood Institute (NHLBI) study. The study was designed to test whether raising HDL "good" cholesterol by adding Niaspan to simvastatin would provide an additional 25 percent reduction in cardiovascular ... read more

ABBOTT PARK, Ill., Nov. 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced positive long-term data from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Five-year results from the first stage and two-year and 18-month data ... read more

ABBOTT PARK, Ill., Nov. 8, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA® (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis (AS). Improvements in disease ... read more

ABBOTT PARK, Ill., Nov. 7, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the Phase 3 ABILITY-1 study of HUMIRA® (adalimumab) in patients with active non-radiographic axial spondyloarthritis (axSpA). AxSpA is a debilitating condition that primarily presents with inflammatory low back pain and can be accompanied by ... read more

ABBOTT PARK, Ill., Nov. 6, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA® (adalimumab) plus methotrexate (MTX) for up to eight years in patients with early moderate to severe rheumatoid arthritis (RA) and up ... read more

ABBOTT PARK, Ill., Nov. 3, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the company's schedule of key data presentations at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, to be held Nov. 7 - 11 in San Francisco. New data will be presented on two of Abbott's key ... read more